Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
N. Girard*, S. Ponce Aix, S. Cedres, T. Berghmans, S. Burgers, A. C. Toffart, S. Popat, A. Janssens, R. Gervais, M. Hochstenbag, M. Silva, I. A. Burger, H. Prosch, R. Stahel, E. Xenophontos, Y. Pretzenbaher, A. Neven, S. Peters
*Corresponding author for this work
Research output: Contribution to journal › Article › Research › peer-review
14Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial'. Together they form a unique fingerprint.